Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Sprint Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sprint Bioscience Publishes Scientific Study With New Positive Data from the Vps34 Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Sprint Bioscience","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","amount":"$277.0 million","upfrontCash":"$4.0 million","newsHeadline":"Sprint Bioscience Licenses the Cancer Drug Program Vps34 to Deciphera Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Sprint Bioscience","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","amount":"$316.0 million","upfrontCash":"$3.0 million","newsHeadline":"Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Sprint Bioscience

    Menu

    Sprint Bioscience

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Sprint Bioscience

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience

              Details:

              Under the agreement, Day One receives an exclusive license to develop and commercialize small molecule drug candidates targeting Vaccinia-related kinase 1 (VRK1), for pediatric and adult cancers with high unmet need.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Day One Biopharmaceuticals

              Deal Size: $316.0 million Upfront Cash: $3.0 million

              Deal Type: Licensing Agreement August 16, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sprint Bioscience

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sprint Bioscience Licenses the Cancer Drug Program Vps34 to Deciphera Pharmaceuticals

              Details:

              Sprint Bioscience lead compound SB02024 blocks the autophagy of tumor cells by inhibiting the protein Vps34. When autophagy is blocked, the tumor cells become visible to the immune system again.

              Lead Product(s): SB02024

              Therapeutic Area: Oncology Product Name: SB02024

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Deciphera Pharmaceuticals

              Deal Size: $277.0 million Upfront Cash: $4.0 million

              Deal Type: Licensing Agreement August 03, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sprint Bioscience

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sprint Bioscience Publishes Scientific Study With New Positive Data from the Vps34 Program

              Details:

              The research results show that SB02024 activates the immune system in tumors in malignant melanoma and colorectal cancer.

              Lead Product(s): SB02024

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY